Neutralization of BCL-2/X(L) enhances the cytotoxicity of T-DM1 in vivo

One of the most recent advances in the treatment of HER2+ breast cancer is the development of the antibody-drug conjugate, T-DM1. T-DM1 has proven clinical benefits for patients with advanced and/or metastatic breast cancer who have progressed on prior HER2-targeted therapies. However, T-DM1 resista...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Mol Cancer Ther
Hoofdauteurs: Zoeller, Jason J., Vagodny, Aleksandr, Taneja, Krishan, Tan, Benjamin Y., O’Brien, Neil, Slamon, Dennis J., Sampath, Deepak, Leverson, Joel D., Bronson, Roderick T., Dillon, Deborah A., Brugge, Joan S.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2019
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6758547/
https://ncbi.nlm.nih.gov/pubmed/30962322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0743
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items